PubMed Health⌕ Search

Biomedical subjects

M A Kosmo

Publications and source records attributed to M A Kosmo.

4 recordsLinked to original sources
PubMed1988

Plasma cell leukemia with IgA paraproteinemia and hyperviscosity.

Primary IgA plasma cell leukemia is a rare disorder in which hyperviscosity has not been reported. We studied a patient with plasma cell leukemia and IgA lambda monoclonal gammopathy with an elevated relative serum viscosity and congestive heart failure. Plasmapheresis and chemotherapy were successful in controlling symptoms. We discuss this unusual association and review the literature.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1987

Trisomy 12 in Burkitt-like lymphoma associated with acquired immunodeficiency syndrome.

Cytogenetic abnormalities have been reported in lymphoproliferative disorders, the most common of which is the t(8;14) translocation in Burkitt and Burkitt-like lymphomas. We report a 30-year-old homosexual male with Burkitt-like lymphoma and trisomy 12. This patient presented with persistent generalized lymphadenopathy and subsequently developed advanced lymphoma. Cell surface markers revealed a monoclonal pattern containing mu heavy chain and kappa light chain immunoglobulins. Cytogenetic analysis of bone marrow involved with lymphoma revealed an additional chromosome #12. Mitogen-stimulated cultures of peripheral blood showed a normal 46,XY karyotype. Trisomy 12 has been found in chronic lymphocytic leukemia and in other low-grade B-cell lymphoproliferative disorders, but not in Burkitt-like lymphoma.

Acquired Immunodeficiency Syndrome↗
PubMed1987

Plasma cell leukemia.

In summary, plasma cell leukemia is a rare disorder that can develop spontaneously or evolve in patients with multiple myeloma. The diagnosis is based on laboratory features, including a plasmacytosis exceeding 2 X 10(9)/L or 20% of the differential cell count. Primary plasma cell leukemia should also be considered when fewer plasma cells are present provided that a clonal proliferation is documented. Most clinical characteristics are similar in both types of plasma cell leukemia. Lymphadenopathy and hepatosplenomegaly are more common in the primary form, and lytic bone lesions are more frequent in the secondary form. Patients with primary plasma cell leukemia may initially respond better to chemotherapy, including single agent drugs commonly used in multiple myeloma. However, resistant disease is expected, and most data suggest a median survival of less than 6 months in both types of leukemia. Because patients with primary plasma cell leukemia are in better condition, intensive chemotherapy and approaches such as bone marrow transplantation should be considered, especially in younger patients.

Antineoplastic Combined Chemotherapy Protocols↗